- Location
1
result for "
Exelon Patch
"-
Novartis Obtained FDA Approval for a New 13.3 Mg/24 H Dosage Strength of Its Exelon Patch
Dec 5, 2012Novartis has obtained the US Food and Drug Administration (FDA) approval for a new 13.3 mg/24 h dosage strength of its Exelon Patch (rivastigmine transdermal system), designed to treat patients with mild to moderate Alzheimer's disease. ...
Tags: Alzheimer's disease, Novartis Pharmaceuticals, Exelon Patch
